[1] Hamid R, Gomez M Schulte H, Boroujerdi A, Patel A, Farrelly E. OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real world practice. Int Urogynecol J. 2021;32(1):65 74.
[2] Patiño G, Sánchez C, Iregui J, Fernández J. Guía vejiga hiperactiva no neurogénica en adultos. Guía de la Sociedad Colombiana de Urología. Urol Colomb [Internet]. 2016 [ac- ceso 29 de febrero de 2024];25(1). Disponible en: https://www.redalyc.org/articulo.oa?id=149144780013.
[3] Jayarajan J, Rado- mski S. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol [Internet]. 2012 [acceso 13 de junio de 2023];6(2014). Disponible en: https://www.tandfonline.com/doi/full/10.2147/RRU.S40034
[4] Hu J, Hsu L, Lee W, Chuang Y, Wang H. Role of Urological Botulinum Toxin–A Injection for Overactive Bladder and Voiding Dysfunction in Patients with Parkinson’s Disease or Post-Stroke. Toxins (Basel) [Internet]. 2023 [acceso 13 de junio de 2023];15(2):166. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36828479/
[5] Albanese, A. (2011). Terminology for preparations of botulinum neurotoxins: What a difference a name makes. JAMA, 305(1), 89-90. https://pubmed.ncbi.nlm.nih.gov/21205970/
[6] Información para prescribir actualmente aprobada para el producto Botox® https://www.abbvie.com.co/content/dam/abbvie-dotcom/co/Products/Botox100u/INSColombia.pdf
CO-BUO-240019